Pelthos Therapeutics Announces First Quarter 2026 Financial Results
Pelthos Therapeutics reported Q1 2026 net product revenue of $10.7 million for ZELSUVMI, a 17% increase from $9.1 million in Q4 2025. The company dispensed 7,884 units of ZELSUVMI in Q1 2026, a 25% increase from 6,312 units in Q4 2025, with 3,228 unique prescribers. Pelthos expanded its sales force by adding 14 new sales representative positions, bringing the total to 64 territory managers as of Q1 2026.
Key figures
- Eps Beat
- 0
- Revenue
- 10665000
- Revenue Yoy
- 0
- Units dispensed qoq
- 25%
- Cash balance q1 2026
- 31976000
- Sga expenses q1 2026
- 21104000
- Sga expenses q4 2025
- 18500000
- Sga expenses increase
- 2600000
- Net product revenue qoq
- 17%
- Interest expense q1 2026
- 2353000
- Interest expense q4 2025
- 1314000
- Units prescribed q1 2026
- 7884
- Shares outstanding q1 2026
- 8900000
- Unique prescribers q1 2026
- 3228
- Total units dispensed since launch
- 16774
- Change in fair value of debt q1 2026
- 5203000
- Total unique prescribers since launch
- 4867
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.